GeNeuro SA, a clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoimmune diseases. The company’s lead therapeutic candidate is temelimab, a monoclonal antibody that neutralizes a pathogenic protein of the HERV-W family that has completed a Phase II clinical trials. It is also developing GNC-501 for post-COVID on patients with persistent neuropsychiatric syndromes that is in Phase 2 clinical trials; and GNK301 for sporadic amyotrophic lateral sclerosis which is in preclinical development program. In addition, the company has a collaborative development agreement with The National Institute of Neurological Disorders and Strokes for the development of an antibody program to block the activity of pHERV-K Env; and FondaMental Foundation for the development of diagnostic and therapeutic options for patients with Post-COVID neuropsychiatric syndromes, as well as research collaboration agreement with Northwestern University to confirm evidence of the expression of human endogenous retrovirus W envelope protein (W-ENV or W-ENV) in long-haul COVID patients; and US National Institute of Health for developing new approaches against pHERV-K (K-ENV) protein as a target in the treatment of amyotrophic lateral sclerosis. GeNeuro SA was incorporated in 2006 and is headquartered in Plan-les-Ouates, Switzerland.
Metrics to compare | GNRO | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipGNROPeersSector | |
|---|---|---|---|---|
P/E Ratio | 0.0x | −1.7x | −0.5x | |
PEG Ratio | 0.00 | −0.21 | 0.00 | |
Price/Book | 0.0x | 1.9x | 2.6x | |
Price / LTM Sales | 0.0x | 3.1x | 3.2x | |
Upside (Analyst Target) | 0.0% | 51.6% | 51.2% | |
Fair Value Upside | Unlock | 13.0% | 7.3% | Unlock |